This study aimed to evaluate whether plasma GDF15 concentrations are associated with cognitive performance in individuals with CD and to assess examine the potential of GDF15 as a biomarker of cognitive decline in CD.<h4>Methods</h4>Plasma GDF15 levels were measured in patients with CD before and after botulinum toxin (BoNT) treatment and compared with healthy controls. Here, GDF15 is linked to Mental deterioration.